Efficacy and tolerability of oral bicalutamide in forty postmenopausal women with female pattern hair loss: a retrospective study [0.03%]
口服比卡鲁胺治疗40例绝经后女性型脱发患者的疗效及耐受性：一项回顾性研究
B Ferrer Guillén,D Vega Díez,J M Ricart Vaya et al.
B Ferrer Guillén et al.
Cutaneous squamous cell carcinoma while on vismodegib therapy for locally advanced basal cell carcinoma [0.03%]
伏西戈茋治疗局部晚期基底细胞癌期间发生皮肤鳞状细胞癌
B Sánchez Lafuente,P J Vera García,P Cerezuela Fuentes
B Sánchez Lafuente
Tralokinumab effectiveness in moderate-to-severe atopic dermatitis with palmoplantar eczema [0.03%]
特拉鲁莫单抗治疗中重度伴掌跖型湿疹特应性皮炎的疗效
J J Domínguez-Cruz,F J Navarro-Triviño,Galán-Gutiérrez M et al.
J J Domínguez-Cruz et al.
Perianal cmedones: a case series of five patients and a possible association with previously described perianal cysts [0.03%]
肛周comedo样硬化性斑块：5例报告及与既往报道的肛周囊肿的相关性探讨
P Aarts,Hessel H van der Zee
P Aarts
Second-degree burns: contemporary management, evidence gaps, and practical proposals [0.03%]
二度烧伤的现代治疗、证据缺口及实用建议
J Ugedo Alzaga,E Conde-Montero
J Ugedo Alzaga
V H Pinos León,J Sanchez Villarroel,M B Pazmiño
V H Pinos León
Diagnostic challenges and clinicopathologic findings in leg-type lymphoma: retrospective analysis of a nine-case series [0.03%]
下肢淋巴瘤的诊断挑战及临床病理特征：九例患者的回顾性分析
M Mansilla-Polo,A Agüera-Sánchez,C Godoy-Alba et al.
M Mansilla-Polo et al.
Real-world safety and efficacy profile of JAK inhibitors in pediatric alopecia areata: a multicenter retrospective study [0.03%]
JAK抑制剂治疗儿童斑秃的疗效和安全性：一项多中心回顾性研究
M Mansilla-Polo,C Abril-Pérez,L Berbegal et al.
M Mansilla-Polo et al.
Evaluation of the risk of psoriatic arthritis in patients with psoriasis undergoing biological treatment. Global population study (TRINETX) [0.03%]
生物制剂治疗银屑病患者发生银屑病关节炎风险的评估：全球人群研究（TRINETX）
R Rivera-Diaz,B Joven,G Hernandez-Ibarburu et al.
R Rivera-Diaz et al.
Introduction: Psoriatic arthritis (PsA) is an inflammatory condition associated with psoriasis (PsO), with variable prevalence ranging from 6% to 42%. Despite the known link between PsO and PsA, reliable biomarkers for pr...
Adverse events in patients aged ≥ 85 vs < 85 years with advanced basal cell carcinoma treated with sonidegib [0.03%]
索立德吉治疗85岁及以上与以下晚期基底细胞癌患者的安全性分析
A Jiménez-Sánchez,Ó Muñoz Moreno-Arrones,S Béa-Ardebol et al.
A Jiménez-Sánchez et al.